9 Macular Degeneration Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Macular Degeneration Studies in Phoenix

NCT03683251Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) w...

Phoenix, AZPHASE31,000 participantsHoffmann-La Roche

View Study Details

NCT06541704Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...

Phoenix, AZPHASE3975 participantsRegeneron Pharmaceuticals

View Study Details

NCT07482176Recruiting

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-...

Phoenix, AZPHASE3534 participantsAdverum Biotechnologies, Inc.

View Study Details

NCT07215390Recruiting

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacopla...

Phoenix, AZPHASE2240 participantsApellis Pharmaceuticals, Inc.

View Study Details

NCT06990269Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assess...

Phoenix, AZPHASE2240 participantsADARx Pharmaceuticals, Inc.

View Study Details

NCT07770828Recruiting

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm...

Phoenix, AZPHASE3237 participantsOcugen

View Study Details

NCT05197270Recruiting

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-1...

Phoenix, AZPHASE1215 participants4D Molecular Therapeutics

View Study Details

NCT03178149Recruiting

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-se...

Phoenix, AZPHASE142 participantsAstellas Institute for Regenerative Medicine

View Study Details

NCT07630649Recruiting

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult p...

Phoenix, AZPHASE215 participantsAdverum Biotechnologies, Inc.

View Study Details

About Macular Degeneration Clinical Trials in Phoenix

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.

There are currently 9 macular degeneration clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 3,498 participants. Research is being sponsored by Hoffmann-La Roche, Regeneron Pharmaceuticals, Adverum Biotechnologies, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Macular Degeneration Clinical Trials in Phoenix — FAQ

Are there macular degeneration clinical trials in Phoenix?

Yes, there are 9 macular degeneration clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What macular degeneration treatments are being tested?

The 9 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.

Data updated October 15, 2026 from ClinicalTrials.gov